PLYX

Polaryx is a clinical-stage biotech with no approved products, no product revenue, and by its own admission 'a limited operating history.' The entire equity thesis rests on PLX-200, an oral repurposed small molecule the company itself calls the one it is 'substantially dependent on the success of.' Everything else in the pipeline — PLX-300, PLX-100, PLX-400 — is preclinical or IND-enabling. There is nothing here to value on fundamentals in the normal sense: total assets are $5.17M, essentially all of it the $5.14M cash pile, and stockholders' equity is just $4.57M against a $99.6M accumulated deficit. The 'improving' net loss (-$8.98M vs -$30.4M) is not operational progress — operating income actually deteriorated 79.7% and operating cash burn worsened 53.3% to -$3.94M as R&D expense more than doubled (+122.9%). The headline loss narrowed on non-operating/non-cash items, not the business getting healthier.

The balance sheet looks superficially clean (liabilities/equity of just 0.13x), but that misreads the situation: a company with no debt and no revenue is not 'safe,' it is simply pre-financing. With ~$5.1M of cash and operating burn already near $4M — and about to accelerate hard as the Phase 2 SOTERIA basket trial launches in 2H 2026 — the runway is well under two years and likely much less once trial costs hit. The 10-K states plainly the company 'will require substantial additional capital' and, absent it, may be 'forced to delay, reduce or eliminate clinical trials.' For a 47.3M-share company trading at $2.81 (roughly a ~$133M implied cap on the given share count), a near-certain dilutive raise is the base case, and it will come before any pivotal data de-risks the story.